Patisiran supply under the 2027 framework agreement

Summary

Amgros I/S is procuring an estimated 8,900 units of the medicine Patisiran (2 mg/ml concentrate for infusion solution) under one independently awarded, non-exclusive framework agreement for Danish hospital pharmacies, with possible onward supply to the Faroe Islands and Greenland. The ordinary purchasing period is 1 May 2027 to 30 April 2028; the agreement may be extended up to twice by up to six months each. The estimated and maximum value stated for the contract is DKK 18.3 million, while actual demand may differ substantially from the estimate.